![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CRK |
Gene summary for CRK |
![]() |
Gene information | Species | Human | Gene symbol | CRK | Gene ID | 1398 |
Gene name | CRK proto-oncogene, adaptor protein | |
Gene Alias | CRKII | |
Cytomap | 17p13.3 | |
Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | A0A0S2Z3K9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1398 | CRK | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.52e-02 | -1.71e-01 | 0.0155 |
1398 | CRK | HTA11_347_2000001011 | Human | Colorectum | AD | 5.62e-11 | 5.00e-01 | -0.1954 |
1398 | CRK | HTA11_411_2000001011 | Human | Colorectum | SER | 8.31e-05 | 8.78e-01 | -0.2602 |
1398 | CRK | HTA11_83_2000001011 | Human | Colorectum | SER | 4.62e-02 | 4.63e-01 | -0.1526 |
1398 | CRK | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.13e-05 | 6.12e-01 | -0.059 |
1398 | CRK | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.79e-02 | -1.96e-01 | 0.3859 |
1398 | CRK | A002-C-010 | Human | Colorectum | FAP | 2.08e-02 | -2.13e-01 | 0.242 |
1398 | CRK | A001-C-207 | Human | Colorectum | FAP | 1.95e-04 | -3.53e-01 | 0.1278 |
1398 | CRK | A015-C-203 | Human | Colorectum | FAP | 1.71e-22 | -3.60e-01 | -0.1294 |
1398 | CRK | A015-C-204 | Human | Colorectum | FAP | 7.64e-04 | -2.70e-01 | -0.0228 |
1398 | CRK | A014-C-040 | Human | Colorectum | FAP | 2.14e-02 | -4.20e-01 | -0.1184 |
1398 | CRK | A002-C-201 | Human | Colorectum | FAP | 1.76e-06 | -2.31e-01 | 0.0324 |
1398 | CRK | A001-C-119 | Human | Colorectum | FAP | 8.38e-04 | -3.59e-01 | -0.1557 |
1398 | CRK | A001-C-108 | Human | Colorectum | FAP | 1.18e-12 | -3.04e-01 | -0.0272 |
1398 | CRK | A002-C-205 | Human | Colorectum | FAP | 2.60e-13 | -3.06e-01 | -0.1236 |
1398 | CRK | A001-C-104 | Human | Colorectum | FAP | 5.59e-03 | -2.08e-01 | 0.0184 |
1398 | CRK | A015-C-005 | Human | Colorectum | FAP | 2.05e-05 | -3.24e-01 | -0.0336 |
1398 | CRK | A015-C-006 | Human | Colorectum | FAP | 4.68e-10 | -4.21e-01 | -0.0994 |
1398 | CRK | A015-C-106 | Human | Colorectum | FAP | 8.27e-09 | -1.98e-01 | -0.0511 |
1398 | CRK | A002-C-114 | Human | Colorectum | FAP | 5.30e-10 | -2.53e-01 | -0.1561 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:1901653110 | Skin | cSCC | cellular response to peptide | 124/4864 | 359/18723 | 1.75e-04 | 1.49e-03 | 124 |
GO:001072016 | Skin | cSCC | positive regulation of cell development | 105/4864 | 298/18723 | 2.30e-04 | 1.89e-03 | 105 |
GO:199009019 | Skin | cSCC | cellular response to nerve growth factor stimulus | 26/4864 | 53/18723 | 2.58e-04 | 2.10e-03 | 26 |
GO:000283122 | Skin | cSCC | regulation of response to biotic stimulus | 112/4864 | 327/18723 | 5.00e-04 | 3.76e-03 | 112 |
GO:199008918 | Skin | cSCC | response to nerve growth factor | 26/4864 | 56/18723 | 7.59e-04 | 5.27e-03 | 26 |
GO:00028326 | Skin | cSCC | negative regulation of response to biotic stimulus | 43/4864 | 108/18723 | 1.12e-03 | 7.36e-03 | 43 |
GO:0034446110 | Skin | cSCC | substrate adhesion-dependent cell spreading | 43/4864 | 108/18723 | 1.12e-03 | 7.36e-03 | 43 |
GO:000836025 | Skin | cSCC | regulation of cell shape | 57/4864 | 154/18723 | 1.61e-03 | 9.90e-03 | 57 |
GO:002198712 | Skin | cSCC | cerebral cortex development | 44/4864 | 114/18723 | 2.05e-03 | 1.22e-02 | 44 |
GO:002154311 | Skin | cSCC | pallium development | 61/4864 | 169/18723 | 2.27e-03 | 1.33e-02 | 61 |
GO:004801321 | Skin | cSCC | ephrin receptor signaling pathway | 23/4864 | 51/18723 | 2.41e-03 | 1.38e-02 | 23 |
GO:0010770110 | Skin | cSCC | positive regulation of cell morphogenesis involved in differentiation | 32/4864 | 79/18723 | 3.32e-03 | 1.81e-02 | 32 |
GO:004578529 | Skin | cSCC | positive regulation of cell adhesion | 139/4864 | 437/18723 | 3.39e-03 | 1.84e-02 | 139 |
GO:004508812 | Skin | cSCC | regulation of innate immune response | 75/4864 | 218/18723 | 3.40e-03 | 1.84e-02 | 75 |
GO:001081128 | Skin | cSCC | positive regulation of cell-substrate adhesion | 46/4864 | 123/18723 | 3.41e-03 | 1.85e-02 | 46 |
GO:001097522 | Skin | cSCC | regulation of neuron projection development | 141/4864 | 445/18723 | 3.72e-03 | 1.99e-02 | 141 |
GO:001660110 | Skin | cSCC | Rac protein signal transduction | 19/4864 | 42/18723 | 5.36e-03 | 2.70e-02 | 19 |
GO:00458246 | Skin | cSCC | negative regulation of innate immune response | 28/4864 | 71/18723 | 8.86e-03 | 4.07e-02 | 28 |
GO:000697930 | Thyroid | HT | response to oxidative stress | 81/1272 | 446/18723 | 2.53e-16 | 1.17e-13 | 81 |
GO:000030229 | Thyroid | HT | response to reactive oxygen species | 47/1272 | 222/18723 | 1.97e-12 | 4.05e-10 | 47 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa05100 | Colorectum | AD | Bacterial invasion of epithelial cells | 44/2092 | 77/8465 | 1.13e-09 | 2.22e-08 | 1.42e-08 | 44 |
hsa04666 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
hsa05135 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa05170 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa05220 | Colorectum | AD | Chronic myeloid leukemia | 31/2092 | 76/8465 | 1.41e-03 | 8.46e-03 | 5.39e-03 | 31 |
hsa04015 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
hsa05163 | Colorectum | AD | Human cytomegalovirus infection | 75/2092 | 225/8465 | 2.00e-03 | 1.10e-02 | 7.01e-03 | 75 |
hsa05211 | Colorectum | AD | Renal cell carcinoma | 28/2092 | 69/8465 | 2.58e-03 | 1.37e-02 | 8.75e-03 | 28 |
hsa04810 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa04510 | Colorectum | AD | Focal adhesion | 67/2092 | 203/8465 | 4.40e-03 | 2.17e-02 | 1.38e-02 | 67 |
hsa04012 | Colorectum | AD | ErbB signaling pathway | 31/2092 | 85/8465 | 1.02e-02 | 3.91e-02 | 2.50e-02 | 31 |
hsa051311 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa051001 | Colorectum | AD | Bacterial invasion of epithelial cells | 44/2092 | 77/8465 | 1.13e-09 | 2.22e-08 | 1.42e-08 | 44 |
hsa046661 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
hsa051351 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa047221 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa051701 | Colorectum | AD | Human immunodeficiency virus 1 infection | 72/2092 | 212/8465 | 1.40e-03 | 8.46e-03 | 5.39e-03 | 72 |
hsa052201 | Colorectum | AD | Chronic myeloid leukemia | 31/2092 | 76/8465 | 1.41e-03 | 8.46e-03 | 5.39e-03 | 31 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CRK | SNV | Missense_Mutation | novel | c.608N>A | p.Gly203Asp | p.G203D | P46108 | protein_coding | deleterious(0.03) | benign(0.006) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
CRK | SNV | Missense_Mutation | novel | c.777G>T | p.Glu259Asp | p.E259D | P46108 | protein_coding | tolerated(0.07) | benign(0.118) | TCGA-AJ-A8CW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CRK | SNV | Missense_Mutation | rs145983279 | c.562G>A | p.Glu188Lys | p.E188K | P46108 | protein_coding | deleterious(0.02) | benign(0.438) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
CRK | SNV | Missense_Mutation | novel | c.795N>T | p.Lys265Asn | p.K265N | P46108 | protein_coding | deleterious(0.02) | probably_damaging(0.955) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
CRK | SNV | Missense_Mutation | rs748897674 | c.686N>T | p.Pro229Leu | p.P229L | P46108 | protein_coding | deleterious(0.02) | benign(0.157) | TCGA-D1-A16R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CRK | SNV | Missense_Mutation | novel | c.385N>A | p.Leu129Ile | p.L129I | P46108 | protein_coding | tolerated(0.23) | benign(0) | TCGA-E6-A1M0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
CRK | SNV | Missense_Mutation | novel | c.721N>G | p.Arg241Gly | p.R241G | P46108 | protein_coding | deleterious(0) | probably_damaging(0.95) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CRK | deletion | Frame_Shift_Del | c.818delN | p.Gly273ValfsTer66 | p.G273Vfs*66 | P46108 | protein_coding | TCGA-55-7725-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |||
CRK | SNV | Missense_Mutation | rs776920144 | c.559N>A | p.Val187Ile | p.V187I | P46108 | protein_coding | tolerated(0.09) | possibly_damaging(0.63) | TCGA-CN-5365-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
CRK | SNV | Missense_Mutation | c.172N>G | p.Ser58Ala | p.S58A | P46108 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-CH-5748-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |